dc.contributor.author | Kerbrat, P. | en |
dc.contributor.author | Dieras, V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Ravaud, A. | en |
dc.contributor.author | Wanders, J. | en |
dc.contributor.author | Fumoleau, P. | en |
dc.creator | Kerbrat, P. | en |
dc.creator | Dieras, V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Ravaud, A. | en |
dc.creator | Wanders, J. | en |
dc.creator | Fumoleau, P. | en |
dc.date.accessioned | 2018-06-22T09:53:46Z | |
dc.date.available | 2018-06-22T09:53:46Z | |
dc.date.issued | 2003 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42011 | |
dc.description.abstract | LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had been previously treated with two lines of chemotherapy for advanced disease. Patients received LU 103793 at a dose of 2.5 mg/m2/day over 5 min for 5 consecutive days every 3 weeks. Thirty-four patients were enrolled and 23 patients were eligible for the evaluation of efficacy. Eleven patients experienced grade 4 neutropenia. Other related grade 3/4 adverse events included asthenia (three patients), stomatitis (1), myalgia (1) and increase of serum bilirubin (2). The main toxicity was hypertension occurring in seven out of 34 patients. There were no objective responses, 7 patients had stable disease. These results do not support the further evaluation of LU 103793 in metastatic breast cancer patients using this dose and schedule. © 2003 Elsevier Science Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | European journal of cancer | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Controlled study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Drug response | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Drug efficacy | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Myalgia | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Drug tolerability | en |
dc.subject | Fever | en |
dc.subject | Metastasis | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Malaise | en |
dc.subject | Hypertension | en |
dc.subject | Vomiting | en |
dc.subject | Breast cancer | en |
dc.subject | Breast carcinoma | en |
dc.subject | Nausea | en |
dc.subject | Dose calculation | en |
dc.subject | Bilirubin blood level | en |
dc.subject | Hyperbilirubinemia | en |
dc.subject | Bilirubin | en |
dc.subject | Phase ii | en |
dc.subject | Headache | en |
dc.subject | Asthenia | en |
dc.subject | Time | en |
dc.subject | Cemadotin | en |
dc.subject | Dolastatin | en |
dc.subject | Heart | en |
dc.subject | Liver | en |
dc.subject | Lu 103793 | en |
dc.subject | Oligopeptides | en |
dc.title | Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(02)00531-2 | |
dc.description.volume | 39 | |
dc.description.issue | 3 | |
dc.description.startingpage | 317 | |
dc.description.endingpage | 320 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |